Imagine what you can accomplish with 360° insight into the tumor immune response

Veracyte translates the complex tumor immune response into a clear path forward, whether the insight you need is to guide treatment decisions, inform biomarker development or advance therapeutic platforms.

Imagine what you can accomplish with 360° insight into the tumor immune response

FOR CLINICIANS

Maximize patient survival rates with an assessment of the tumor immune response using Immunoscore®, an in vitro diagnostic test that measures the patient’s immune response at the tumor site.

IMMUNOSCORE IN:

FOR BIOPHARMA PARTNERS

Gain actionable insight to advance your biomarker, companion diagnostics and therapeutic clinical trials with our multi-omic analysis of the tumor immune response and unique Immunogram report.

FOR PATIENTS

Find out how Immunoscore® can help your doctor develop a treatment plan personalized for you, based on your unique tumor immune response.

PATIENT INFORMATION FOR:

FOR IVD PARTNERS

Turn our experience into your success by partnering with Veracyte for any or all stages of your IVD development and manufacturing processes.

'I think now we have got the tools on hand to help us personalize treatment for patients, and one of those tools would be the Immunoscore®'

Dr Su Pin Choo

Curie Oncology, Singapore

background-collage-mobile@2x

ABOUT US

Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our immuno-oncology diagnostic products and services are used to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr. Jérôme Galon, the company provides a unique range of immune scoring solutions, including the Immunoscore® assay for assessing the immune contexture of a tumor.

Improving patient’s lives today and into the future, Veracyte translates the complexities of the tumor immune response into a clear path forward.

icons-patients (2)

100+

Patients tested/week

icons-biopharma

40

Biopharma partners

icons-scientific-publications

27

Scientific publications

UPCOMING EVENTS

    BioWin Day 2021

    From 09 Dec To 09 Dec
    Virtual

    Biotechgate Digital Partnering

    From 29 Nov To 03 Dec
    Virtual

    16TH ANNUAL NEW ORLEANS FALL CANCER MEETING

    From 19 Nov To 21 Nov
    New Orleans, US

    SITC 2021

    From 10 Nov To 14 Nov
    Washington DC

Latest News

    VERACYTE COMPLETES ACQUISITION OF HALIODX

    3 August, 2021

    HALIODX AND VERACYTE SET PROPOSED ACQUISITION TERMS

    1 June, 2021

    IMMUNOSCORE® IS NOW AVAILABLE IN RECTAL CANCER FOR EXPERT CLINICAL CENTERS THROUGH AN INNOVATION ACCESS PROGRAM

    11 May, 2021

    HALIODX PARTNERS WITH DASA, THE LARGEST DIAGNOSTICS PROVIDER IN LATIN AMERICA, TO MAKE IMMUNOSCORE® AVAILABLE IN BRAZIL

    10 December, 2020

UPCOMING EVENTS

    BioWin Day 2021

    From 09 Dec To 09 Dec

    Virtual

    Biotechgate Digital Partnering

    From 29 Nov To 03 Dec

    Virtual

Latest News

    VERACYTE COMPLETES ACQUISITION OF HALIODX

    3 August, 2021

    HALIODX AND VERACYTE SET PROPOSED ACQUISITION TERMS

    1 June, 2021

Featured Content